Article Figures & Data
Tables
- Table 1.
Selected characteristics of controls, invasive ductal carcinoma cases, and invasive lobular carcinoma cases
Controls (n = 1,474) Ductal carcinoma (n = 1,199) Lobular carcinoma (n = 739) n (%) n (%) n (%) Reference age (y) 55-59 137 (9.3) 140 (11.7) 162 (21.9) 60-64 121 (8.2) 125 (10.4) 139 (18.8) 65-69 442 (30.0) 341 (28.4) 189 (25.5) 70-74 478 (32.4) 380 (31.7) 195 (26.4) 75-79 296 (20.1) 213 (17.7) 54 (7.3) Race White (non-Hispanic) 1,346 (91.3) 1,116 (93.1) 688 (93.1) Black 45 (3.1) 22 (1.8) 16 (2.2) Asian/Pacific Islander 38 (2.6) 35 (2.9) 11 (1.5) Other/unknown 45 (3.0) 26 (2.2) 24 (3.2) Education Less than high school 177 (12.0) 127 (10.6) 53 (7.2) High school 520 (35.3) 403 (33.6) 221 (29.9) Some college 467 (31.7) 407 (33.9) 238 (32.2) College/college graduate 309 (21.0) 262 (21.9) 227 (30.7) Missing 1 0 0 Parity Nulliparous 130 (8.8) 126 (10.5) 99 (13.4) Parous 1,344 (91.2) 1,073 (89.5) 640 (86.6) Age at first birth (y) 14-19 273 (20.4) 201 (18.8) 124 (19.5) 20-24 650 (48.5) 519 (48.6) 306 (48.0) 25-29 305 (22.7) 244 (22.8) 136 (21.4) 30-42 113 (8.4) 105 (9.8) 71 (11.1) Missing 133 130 102 Use of oral contraceptives (mo) 0 907 (63.4) 721 (63.0) 339 (49.2) 6-59 297 (20.8) 219 (19.1) 193 (28.0) 60-409 227 (15.9) 204 (17.8) 157 (22.8) Missing 43 55 50 Recency of menopausal hormone therapy use Never user 433 (32.4) 323 (29.9) 134 (19.3) Former user of hormone therapy 246 (18.4) 185 (17.1) 96 (13.9) Current EHT user 450 (33.6) 297 (27.5) 195 (28.1) Current CHT user 209 (15.6) 276 (25.5) 268 (38.7) Missing 136 118 46 First-degree family history of breast cancer No 1,153 (83.4) 878 (77.3) 556 (77.3) Yes 229 (16.6) 258 (22.7) 163 (22.7) Missing 92 63 20 Body mass index, quartiles (kg/m2) ≤23.16 363 (25.4) 265 (22.6) 210 (29.0) 23.17-26.44 372 (26.1) 309 (26.4) 154 (21.3) 26.45-30.82 343 (24.0) 283 (24.1) 200 (27.6) ≥30.83 350 (24.5) 315 (26.9) 160 (22.1) Missing 46 27 15 Abbreviations: EHT, estrogen hormone therapy; CHT, combined hormone therapy.
- Table 2.
Relationship between a history of migraine and risks of invasive ductal and invasive lobular breast carcinomas
Controls (n = 1,474) Ductal carcinoma (n = 1,199) Lobular carcinoma (n = 739) n (%) n (%) OR* (95% CI) n (%) OR* (95% CI) Never diagnosed with migraine 1,202 (82) 1,037 (87) 1.00 (reference) 630 (85) 1.00 (reference) Ever diagnosed with migraine 272 (19) 162 (14) 0.67 (0.54-0.82)† 109 (15) 0.68 (0.52-0.90)† Age at migraine diagnosis (y) <20 73 (5) 32 (3) 0.50 (0.33-0.76)† 23 (3) 0.55 (0.33-0.91)† 20-39 110 (8) 80 (7) 0.83 (0.62-1.13) 48 (7) 0.77 (0.53-1.12) ≥40 89 (6) 50 (4) 0.62 (0.43-0.89)† 36 (5) 0.62 (0.41-0.95)† P value for difference across age categories 0.52 0.85 Ever use of prescription migraine medications No 127 (9) 67 (6) 0.58 (0.43-0.79)† 53 (7) 0.65 (0.46-0.93)† Yes 144 (10) 92 (8) 0.73 (0.56-0.97)† 55 (8) 0.69 (0.49-0.97)† P value for difference across medication categories 0.25 0.98 - Table 3.
Relationship between a history of migraine and risks of invasive ductal and invasive lobular breast carcinomas by joint ER/PR status
Ductal carcinoma Controls (n = 1,474) ER+/PR+ (n = 855) ER+/PR− (n = 133) ER−/PR− (n = 147) n (%) n (%) OR* (95% CI) n (%) OR* (95% CI) n (%) OR* (95% CI) Never diagnosed with migraine 1,202 (82) 739 (87) 1.00 (reference) 120 (90) 1.00 (reference) 121 (82) 1.00 (reference) Ever diagnosed with migraine 272 (19) 114 (13) 0.65 (0.51-0.83)† 13 (10) 0.49 (0.27-0.88)† 26 (18) 0.87 (0.56-1.36) Age at migraine diagnosis (y) <20 73 (5) 26 (3) 0.56 (0.35-0.88)† 2 (2) 0.28 (0.07-1.16) 3 (2.0) 0.37 (0.11-1.19) 20-39 110 (8) 57 (7) 0.82 (0.59-1.15) 6 (5) 0.56 (0.24-1.30) 15 (10) 1.24 (0.70-2.21) ≥40 89 (6) 31 (4) 0.53 (0.35-0.81)† 5 (4) 0.57 (0.23-1.44) 8 (5) 0.82 (0.39-1.74) P value for difference across age categories 0.80 0.43 0.37 Ever use of prescription migraine medications No 127 (9) 47 (6) 0.56 (0.39-0.79)† 6 (5) 0.48 (0.21-1.11) 11 (8) 0.79 (0.41-1.51) Yes 144 (10) 65 (8) 0.72 (0.53-0.98)† 6 (5) 0.43 (0.19-1.00)† 15 (10) 0.95 (0.54-1.67) P value for difference across medication categories 0.27 0.85 0.66 Lobular carcinoma Controls (n = 1,474) ER+/PR+ (n = 560) ER+/PR− (n = 110) n (%) n (%) OR* (95% CI) n (%) OR* (95% CI) Never diagnosed with migraine 1,202 (82) 481 (86) 1.00 (reference) 92 (84) 1.00 (reference) Ever diagnosed with migraine 272 (19) 78 (14) 0.63 (0.47-0.85)† 18 (16) 0.80 (0.47-1.36) Age at migraine diagnosis (y) <20 73 (5) 19 (4) 0.59 (0.34-1.03) 3 (3) 0.50 (0.15-1.65) 20-39 110 (8) 34 (7) 0.73 (0.47-1.13) 6 (6) 0.70 (0.30-1.66) ≥40 89 (6) 23 (5) 0.50 (0.30-0.82)† 9 (8) 1.10 (0.53-2.29) P value for difference across age categories 0.60 0.20 Ever use of prescription migraine medications No 127 (5) 35 (6) 0.57 (0.38-0.86)† 10 (9) 0.91 (0.46-1.81) Yes 144 (10) 42 (8) 0.68 (0.46-1.00) 8 (7) 0.70 (0.33-1.49) P value for difference across medication categories 0.53 0.60